Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2020



(Exact name of registrant as specified in its charter)







(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


395 Oyster Point Boulevard, Suite 400

South San Francisco, California



(Address of principal executive offices)


(Zip Code)

Registrant’s telephone number, including area code: (650) 266-3500

Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value


The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Item 7.01

Regulation FD Disclosure.

Sunesis Pharmaceuticals, Inc., or the Company, is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of a PowerPoint presentation (the “Presentation”), to be used by the Company at various meetings with certain investors. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing or other means. A copy of the Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information contained in the Presentation should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Current Report on Form 8-K. By furnishing this Current Report on Form 8-K and furnishing the Presentation, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including without limitation the Presentation. The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the Presentation is based.

The information furnished in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

The Company is providing the following preliminary results for the ongoing vecabrutinib clinical trial. Two of the three chronic lymphocytic leukemia (“CLL”) patients in Cohort 6 (400mg twice daily) had stable disease upon first response assessments including a patient with a 48% reduction in tumor burden. One patient was determined to have progressive disease but will remain on study as the investigator has determined that the patient is receiving benefit. All three patients remain on study and are in cycle 5. The status of patients being treated in Cohort 7 (500mg twice daily) is also being updated. Three CLL patients and two mantle cell lymphoma patients remain on study at the 500 mg dose level. Additional patients continue to be evaluated for this cohort, and the Company is on track to announce first response assessments for Cohort 7 in the second quarter.

These are preliminary data from an ongoing clinical trial and should be considered with caution and not relied upon as indicative of future clinical results.

Item 9.01. Financial Statements and Exhibits.















Sunesis Update Presentation March 2020



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


















Dated: March 18, 2020






/s/ William P. Quinn







William P. Quinn







Chief Financial Officer, Senior Vice President, Finance and Corporate Development




Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Sunesis Pharmaceuticals Charts.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Sunesis Pharmaceuticals Charts.